Dr. Farrukh Awan Explains Syk Inhibitor in CLL

Farrukh Awan, MBBS
Published: Wednesday, Feb 24, 2016



Farrukh Awan, MBBS, assistant professor of internal medicine, Ohio State University, discusses the role for spleen tyrosine kinase (Syk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL).

Therapy for CLL patients that have failed kinase inhibitors is not very well defined. There is a great need for an agent for patients that have relapsed after either PI3 kinase or bruton's tyrosine kinase (BTK) inhibitors, says Awan.

Syk inhibitor, a compound that is located upstream of BTK and is part of the B-cell receptor signaling pathway, may be a promising option for relapsed patients.

Early results have shown that it is active and well-tolerated in CLL. Syk inhibitor has the potential to maintain quality of life and provide decease control for patients who rapidly progress after failing kinase inhibitors, says Awan.



Farrukh Awan, MBBS, assistant professor of internal medicine, Ohio State University, discusses the role for spleen tyrosine kinase (Syk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL).

Therapy for CLL patients that have failed kinase inhibitors is not very well defined. There is a great need for an agent for patients that have relapsed after either PI3 kinase or bruton's tyrosine kinase (BTK) inhibitors, says Awan.

Syk inhibitor, a compound that is located upstream of BTK and is part of the B-cell receptor signaling pathway, may be a promising option for relapsed patients.

Early results have shown that it is active and well-tolerated in CLL. Syk inhibitor has the potential to maintain quality of life and provide decease control for patients who rapidly progress after failing kinase inhibitors, says Awan.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x